HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment

The addition to chemotherapy of anti-HER2 drugs such as trastuzumab or pertuzumab has improved outcomes in HER2-positive breast cancer patients. However, resistance to these drugs in some patients remains a major concern. This study examines the possible association between the response to neoadjuva...

ver descrição completa

Detalhes bibliográficos
Autores: Gaibar Alonso, María, Novillo, Apolonia, Romero, Alicia, Fernandez, Ana, Malón, Diego, Antón, Beatriz, Moreno, Amalia
Formato: artículo
Fecha de publicación:2023
País:España
Recursos:Universidad Camilo José Cela (UCJC)
Repositorio:Depósito Digital e-UCJC
OAI Identifier:oai:repositorio.ucjc.edu:20.500.12020/985
Acesso em linha:http://hdl.handle.net/20.500.12020/985
https://doi.org/10.3390/cancers15030763
Access Level:acceso abierto
Palavra-chave:Ciencias Biomédicas
HER2-positive breast cancer
Anti-HER2 treatment
HER2 gene
SNPs
Pathological complete response
Miller–Payne grading
32 Ciencias Médicas
id ES_ff32102f939d2885eaee6f4d86dc0b07
oai_identifier_str oai:repositorio.ucjc.edu:20.500.12020/985
network_acronym_str ES
network_name_str España
repository_id_str
spelling HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 TreatmentGaibar Alonso, MaríaNovillo, ApoloniaRomero, AliciaFernandez, AnaMalón, DiegoAntón, BeatrizMoreno, AmaliaCiencias BiomédicasHER2-positive breast cancerAnti-HER2 treatmentHER2 geneSNPsPathological complete responseMiller–Payne grading32 Ciencias MédicasThe addition to chemotherapy of anti-HER2 drugs such as trastuzumab or pertuzumab has improved outcomes in HER2-positive breast cancer patients. However, resistance to these drugs in some patients remains a major concern. This study examines the possible association between the response to neoadjuvant anti-HER2 treatment in breast cancer patients and the presence of 28 SNPs in 17 genes involved in different cell processes (PON1, CAT, GSTP1, FCGR3, ATM, PIK3CA, HER3, BARD1, LDB2, BRINP1, chr6 intergenic region, RAB22A, TRPC6, LINC01060, EGFR, ABCB1, and HER2). Tumor samples from 50 women with early breast cancer were genotyped using the iPlex®Gold chemistry and MassARRAY platform, and patients were classified as good responders (Miller–Payne tumor grades 4–5) and poor responders (Miller–Payne tumor grades 1–3), as assessed upon surgery after 6 months of treatment. Proportions of patients with the HER2Ala1170Pro (rs1058808) SNP double mutation were higher in good (58.62%) than poor (20%) responders (p = 0.025). Similarly, proportions of patients carrying the synonymous SNP rs2070096 (BARD1Thr351=) (wv + vv) were higher in patients showing a pathological complete response (46.67%) than in those not showing this response (15.15%) (p = 0.031). The SNPs rs1058808 (HER2Ala1170Pro) and rs2070096 (BARD1Thr351=) were identified here as potential biomarkers of a good response to anti-HER2 treatment.MDPI2023info:eu-repo/semantics/articlehttp://hdl.handle.net/20.500.12020/985https://doi.org/10.3390/cancers15030763reponame:Depósito Digital e-UCJCinstname:Universidad Camilo José Cela (UCJC)Inglésinfo:eu-repo/semantics/openAccessoai:repositorio.ucjc.edu:20.500.12020/9852026-05-27T07:36:51Z
dc.title.none.fl_str_mv HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
title HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
spellingShingle HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
Gaibar Alonso, María
Ciencias Biomédicas
HER2-positive breast cancer
Anti-HER2 treatment
HER2 gene
SNPs
Pathological complete response
Miller–Payne grading
32 Ciencias Médicas
title_short HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
title_full HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
title_fullStr HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
title_full_unstemmed HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
title_sort HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
dc.creator.none.fl_str_mv Gaibar Alonso, María
Novillo, Apolonia
Romero, Alicia
Fernandez, Ana
Malón, Diego
Antón, Beatriz
Moreno, Amalia
author Gaibar Alonso, María
author_facet Gaibar Alonso, María
Novillo, Apolonia
Romero, Alicia
Fernandez, Ana
Malón, Diego
Antón, Beatriz
Moreno, Amalia
author_role author
author2 Novillo, Apolonia
Romero, Alicia
Fernandez, Ana
Malón, Diego
Antón, Beatriz
Moreno, Amalia
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Ciencias Biomédicas
HER2-positive breast cancer
Anti-HER2 treatment
HER2 gene
SNPs
Pathological complete response
Miller–Payne grading
32 Ciencias Médicas
topic Ciencias Biomédicas
HER2-positive breast cancer
Anti-HER2 treatment
HER2 gene
SNPs
Pathological complete response
Miller–Payne grading
32 Ciencias Médicas
description The addition to chemotherapy of anti-HER2 drugs such as trastuzumab or pertuzumab has improved outcomes in HER2-positive breast cancer patients. However, resistance to these drugs in some patients remains a major concern. This study examines the possible association between the response to neoadjuvant anti-HER2 treatment in breast cancer patients and the presence of 28 SNPs in 17 genes involved in different cell processes (PON1, CAT, GSTP1, FCGR3, ATM, PIK3CA, HER3, BARD1, LDB2, BRINP1, chr6 intergenic region, RAB22A, TRPC6, LINC01060, EGFR, ABCB1, and HER2). Tumor samples from 50 women with early breast cancer were genotyped using the iPlex®Gold chemistry and MassARRAY platform, and patients were classified as good responders (Miller–Payne tumor grades 4–5) and poor responders (Miller–Payne tumor grades 1–3), as assessed upon surgery after 6 months of treatment. Proportions of patients with the HER2Ala1170Pro (rs1058808) SNP double mutation were higher in good (58.62%) than poor (20%) responders (p = 0.025). Similarly, proportions of patients carrying the synonymous SNP rs2070096 (BARD1Thr351=) (wv + vv) were higher in patients showing a pathological complete response (46.67%) than in those not showing this response (15.15%) (p = 0.031). The SNPs rs1058808 (HER2Ala1170Pro) and rs2070096 (BARD1Thr351=) were identified here as potential biomarkers of a good response to anti-HER2 treatment.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12020/985
https://doi.org/10.3390/cancers15030763
url http://hdl.handle.net/20.500.12020/985
https://doi.org/10.3390/cancers15030763
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Depósito Digital e-UCJC
instname:Universidad Camilo José Cela (UCJC)
instname_str Universidad Camilo José Cela (UCJC)
reponame_str Depósito Digital e-UCJC
collection Depósito Digital e-UCJC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425752778211328
score 15.301603

Registos relacionados